Wide Ranks

ABVC

ABVC Biopharma, Inc.

0.5102

Top Statistics
Market Cap 6 M Forward PE -1.16 Revenue Growth 1817.50 %
Current Ratio 0.33 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.02 Enterprise / Revenue 63.58 Price To Sales Trailing12 Months 45.80
Profitability
Profit Margins 0.00 % Operating Margins -833.72 %
Balance Sheet
Total Cash 199979 Total Cash Per Share 0.0170 Total Debt 2 M
Total Debt To Equity 34.91 Current Ratio 0.33 Book Value Per Share 1.06
All Measures
Short Ratio 70.00 % Message Board Id finmb_325748154 Shares Short Prior Month 131680
Return On Equity -3.20 City Fremont Uuid 0f8af6cd-1e3f-33ab-b7e9-bb4a28098e33
Previous Close 0.5060 First Trade Date Epoch Utc 1 B Book Value 1.06
Beta 0.8160 Total Debt 2 M Volume 52856
Price To Book 0.4813 Last Split Date 1 B Fifty Two Week Low 0.4050
Total Cash Per Share 0.0170 Total Revenue 136396 Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -833.72 %
Net Income To Common -11374071 Short Percent Of Float 0.0194 Implied Shares Outstanding 12 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 108160
Average Volume10days 108160 Total Cash 199979 Next Fiscal Year End 1 B
Revenue Per Share 0.0170 Held Percent Insiders 0.2293 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.5060
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.5912
Open 0.5033 Free Cashflow -3194481 State CA
Dividend Yield 0.00 % Return On Assets -0.4455 Time Zone Short Name EST
Trailing Eps -0.8100 Day Low 0.5033 Address1 44370 Old Warm Springs Boulevard
Shares Outstanding 12 M Price Hint 4 Target High Price 0.0000
Website https://www.abvcpharma.com 52 Week Change -0.5952 Average Volume 145898
Forward Eps -0.4400 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 3.20 % Last Split Factor 1:10 Regular Market Day High 0.5404
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 34.91
Fifty Two Week High 2.45 Day High 0.5404 Shares Short 186190
Regular Market Open 0.5033 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 63.58 Revenue Growth 1817.50 % Shares Percent Shares Out 0.0150
Operating Cashflow -3325643 Currency USD Time Zone Full Name America/New_York
Market Cap 6 M Is_nasdaq_100 False Zip 94538
Quote Type EQUITY Industry Biotechnology Long Name ABVC BioPharma, Inc.
Regular Market Day Low 0.5033 Held Percent Institutions 0.0301 Current Price 0.5102
Enterprise To Ebitda -1.02 Financial Currency USD Current Ratio 0.33
Gross Margins -24.11 % Industry Disp Biotechnology Country United States
Float Shares 9 M Two Hundred Day Average 0.8615 Enterprise Value 8 M
Price To Sales Trailing12 Months 45.80 Forward PE -1.16 Regular Market Volume 52856
Ebitda -8507882 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.

It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.

ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is based in Fremont, California.

ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.